Trial · NCT07911683
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
NCT07911683, Phase 2, Not yet recruiting, BeOne Medicines
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma. Trials, record NCT07911683. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911683
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
- NCT number
- NCT07911683
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- BeOne Medicines
- Conditions
- Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma
- Interventions
- BGB-B2033
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Assessment (ORR) by Independent Review Committee Assessment | Up to approximately 15 months | ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) with confirmation per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on Independent Review Committee (IRC) assessments. |
| Secondary | Duration of Response (DOR) | Up to approximately 2 years | DOR is defined as the time from the first documented response to documented disease progression or death, whichever comes first, based on IRC and investigator assessments |
| Secondary | ORR by Investigator Assessment | Up to approximately 2 years | ORR is defined as the percentage of participants with best overall response of CR or PR with confirmation per RECIST V1.1 |
| Secondary | Progression Free Survival (PFS) | Up to approximately 2 years | PFS is defined as the time from first dose to documented disease progression per RECIST 1.1 or death, whichever occurs first, with separate derivations based on IRC and investigator assessments |
| Secondary | Overall Survival (OS) | Up to approximately 2 years | OS is defined as the time from first dose of study drug to death due to any cause. |
| Secondary | Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-Mediated Adverse Events (iMAEs) | From first dose of study drug to 90 days after last dose; up to approximately 2 years | An adverse event is any unfavorable or unintended sign, symptom, disease, or abnormal laboratory finding that occurs during the study, whether or not it is related to the study drug. A serious adverse event is an AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, results in a congenital anomaly or birth defect, or is medically significant based on the judgment of the study doctor or sponsor. An immune-mediated adverse event (iMAE) is an adverse event caused by an immune system response that may affect organs or tissues and requires appropriate monitoring and management. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911683
GET https://conductscience.org/api/trials/v1/NCT07911683/registered